LU92853I2 - Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine - Google Patents

Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine Download PDF

Info

Publication number
LU92853I2
LU92853I2 LU92853C LU92853C LU92853I2 LU 92853 I2 LU92853 I2 LU 92853I2 LU 92853 C LU92853 C LU 92853C LU 92853 C LU92853 C LU 92853C LU 92853 I2 LU92853 I2 LU 92853I2
Authority
LU
Luxembourg
Prior art keywords
rilpivirine
emtricitabine
protected
pharmaceutically acceptable
combination
Prior art date
Application number
LU92853C
Other languages
English (en)
French (fr)
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92853(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of LU92853I2 publication Critical patent/LU92853I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU92853C 2003-09-03 2015-10-20 Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine LU92853I2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP04787096.9A EP1663240B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (1)

Publication Number Publication Date
LU92853I2 true LU92853I2 (fr) 2015-12-21

Family

ID=34280181

Family Applications (3)

Application Number Title Priority Date Filing Date
LU92853C LU92853I2 (fr) 2003-09-03 2015-10-20 Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
LU92854C LU92854I2 (fr) 2003-09-03 2015-10-21 Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
LU92855C LU92855I2 (fr) 2003-09-03 2015-10-21 Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU92854C LU92854I2 (fr) 2003-09-03 2015-10-21 Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
LU92855C LU92855I2 (fr) 2003-09-03 2015-10-21 Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine

Country Status (24)

Country Link
US (9) US20080200435A1 (lt)
EP (1) EP1663240B2 (lt)
JP (3) JP5507791B2 (lt)
KR (1) KR20060090658A (lt)
CN (1) CN101060844B (lt)
AP (1) AP2109A (lt)
AU (5) AU2004268390B2 (lt)
BE (1) BE2015C053I2 (lt)
CA (1) CA2537095C (lt)
CY (5) CY2015038I1 (lt)
FI (1) FI1663240T4 (lt)
FR (5) FR15C0071I2 (lt)
HR (1) HRP20150798T4 (lt)
HU (5) HUS1500054I1 (lt)
IL (2) IL173438A (lt)
LT (2) LTPA2016045I1 (lt)
LU (3) LU92853I2 (lt)
MX (1) MXPA06002437A (lt)
MY (1) MY169670A (lt)
NL (2) NL300781I1 (lt)
NO (6) NO334877B1 (lt)
NZ (1) NZ545306A (lt)
PL (1) PL1663240T5 (lt)
WO (1) WO2005021001A1 (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
NZ538611A (en) 2002-08-09 2007-03-30 Janssen Pharmaceutica Nv Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
PT1632232E (pt) * 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
PL1632232T6 (pl) * 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
CN101056673A (zh) * 2004-09-02 2007-10-17 詹森药业有限公司 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
CA2577273C (en) * 2004-09-02 2013-11-19 Janssen Pharmaceutica N.V. Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EA011036B1 (ru) * 2004-09-02 2008-12-30 Янссен Фармацевтика Н.В. Фумарат 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP2051703B1 (en) * 2005-12-14 2010-07-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
TWI458483B (zh) * 2006-01-20 2014-11-01 Tibotec Pharm Ltd Ｈｉｖ感染之長期治療
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
WO2009115652A2 (fr) * 2008-01-03 2009-09-24 Universite De La Mediterannee, Aix-Marseille Ii Composition et procedes utilisables lors d'un traitement anti-vih
ES2607107T3 (es) * 2008-12-24 2017-03-29 Janssen Sciences Ireland Uc Dispositivos implantables para tratar el VIH
RU2593790C2 (ru) 2009-12-21 2016-08-10 Янссен Сайенсиз Айрлэнд Юси Разлагаемый удаляемый имплантат для непрерывного высвобождения активного соединения
BR112012018670A2 (pt) 2010-01-27 2018-02-06 Glaxosmithkline Llc combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2013038425A1 (en) * 2011-09-16 2013-03-21 Hetero Research Foundation Rilpivirine hydrochloride
NZ709260A (en) 2012-12-21 2016-07-29 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
ES2970870T3 (es) 2016-10-24 2024-05-31 Janssen Sciences Ireland Unlimited Co Composiciones dispersables
US20210128554A1 (en) * 2016-12-23 2021-05-06 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
BR112019021918A2 (pt) * 2017-04-18 2020-05-26 Cipla Limited Terapia de combinação para uso no tratamento de infecções retroviriais
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
DK0489181T3 (da) 1990-07-19 1996-11-18 Otsuka Pharma Co Ltd Fast præparat
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH07503943A (ja) * 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
ATE184787T1 (de) 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
CN1174741C (zh) 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
RU2239435C2 (ru) 2000-03-30 2004-11-10 Бристол-Маерс Сквибб Компани Гранулы пролонгированного высвобождения, содержащие ставудин
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
KR20040025880A (ko) 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 수용해성이 개선된 의약 조성물
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003043586A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
NZ538611A (en) 2002-08-09 2007-03-30 Janssen Pharmaceutica Nv Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
ES2286471T3 (es) 2002-11-08 2007-12-01 Glaxo Group Limited Composiciones farmaceuticas antivirales.
BR0316209A (pt) 2002-11-15 2005-09-27 Tibotec Pharm Ltd Indolpiridìnio substituìdo como compostos antiinfecciosos
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CA2513527C (en) 2003-02-07 2012-08-14 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of hiv infection
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
ZA200700030B (en) 2004-06-08 2009-06-24 Vertex Pharma Pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP2008538754A (ja) * 2005-04-11 2008-11-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 薬剤を含んだ所定のレイヤパターンを有する複層構造体
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
EP1893180A2 (en) 2005-06-07 2008-03-05 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
WO2007016435A2 (en) 2005-07-28 2007-02-08 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
TWI458483B (zh) 2006-01-20 2014-11-01 Tibotec Pharm Ltd Ｈｉｖ感染之長期治療
SI3366278T1 (sl) 2006-06-23 2024-12-31 Janssen Sciences Ireland Unlimited Company Vodne suspenzije tmc278
WO2008060360A2 (en) * 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
US8426434B2 (en) 2007-07-12 2013-04-23 Tibotec Pharmaceuticals Ltd. Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
US20110257111A1 (en) * 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives

Also Published As

Publication number Publication date
NO2014030I2 (no) 2014-12-18
CA2537095C (en) 2012-05-29
AU2016210733A1 (en) 2016-08-25
CY2015038I2 (el) 2016-08-31
IL213104A0 (en) 2011-07-31
FR16C1022I1 (fr) 2017-02-03
PL1663240T3 (pl) 2015-10-30
NL300781I2 (lt) 2016-04-19
HRP20150798T4 (hr) 2023-06-09
NO2016026I1 (no) 2016-12-20
US20180228800A1 (en) 2018-08-16
IL173438A (en) 2012-03-29
AU2014203484A1 (en) 2014-07-17
FR16C1024I1 (fr) 2017-02-03
CY2016049I1 (el) 2017-07-12
CY2015040I1 (el) 2016-08-31
NL300781I1 (lt) 2016-04-19
NO2016025I1 (lt) 2016-12-20
NZ545306A (en) 2009-11-27
NO2014031I1 (no) 2015-01-05
FI1663240T4 (fi) 2023-04-25
NO2014032I2 (no) 2014-12-18
HUS1500053I1 (hu) 2016-03-29
CN101060844B (zh) 2012-01-04
HUS1600058I1 (hu) 2017-02-28
JP5820045B2 (ja) 2015-11-24
AP2109A (en) 2010-02-26
JP2015044839A (ja) 2015-03-12
LTC1663240I2 (lt) 2022-05-25
AP2006003551A0 (en) 2006-04-30
NO334877B1 (no) 2014-06-23
MXPA06002437A (es) 2006-06-20
LU92854I2 (fr) 2015-12-21
CN101060844A (zh) 2007-10-24
NL300768I1 (lt) 2015-12-16
US20140349971A1 (en) 2014-11-27
US20100029591A1 (en) 2010-02-04
EP1663240B2 (en) 2023-03-01
NO2014032I1 (no) 2015-01-05
NL300768I2 (nl) 2023-08-09
NO2014030I1 (no) 2015-01-05
KR20060090658A (ko) 2006-08-14
NO20061374L (no) 2006-03-27
HUS1500054I1 (hu) 2016-03-29
US20080200435A1 (en) 2008-08-21
AU2011201123A1 (en) 2011-04-07
AU2004268390B2 (en) 2011-03-31
NO2014031I2 (no) 2014-12-18
US20220008417A1 (en) 2022-01-13
PL1663240T5 (pl) 2024-02-26
AU2016210733B2 (en) 2018-11-08
LTPA2016045I1 (lt) 2017-01-10
US20190216807A1 (en) 2019-07-18
EP1663240B1 (en) 2015-04-22
FR15C0072I1 (lt) 2015-04-12
IL173438A0 (en) 2006-06-11
CY2015039I1 (el) 2016-08-31
AU2004268390A1 (en) 2005-03-10
CY2016048I1 (el) 2017-07-12
CY2015039I2 (el) 2016-08-31
CY2015038I1 (el) 2016-08-31
HUS1500052I1 (hu) 2016-03-29
JP5507791B2 (ja) 2014-05-28
US20170100398A1 (en) 2017-04-13
FR15C0072I2 (fr) 2019-05-17
CY2016048I2 (el) 2017-07-12
HRP20150798T1 (hr) 2015-09-11
CY2015040I2 (el) 2016-08-31
AU2014203484B2 (en) 2016-09-29
US8841310B2 (en) 2014-09-23
HUS1600059I1 (hu) 2017-02-28
LU92855I2 (fr) 2015-12-21
WO2005021001A1 (en) 2005-03-10
FR15C0073I1 (lt) 2015-04-12
US20150283135A1 (en) 2015-10-08
CA2537095A1 (en) 2005-03-10
LTPA2016044I1 (lt) 2017-01-10
IL213104A (en) 2016-02-29
BE2015C053I2 (lt) 2023-12-14
AU2011201123B2 (en) 2013-10-10
JP2007520443A (ja) 2007-07-26
AU2019200813A1 (en) 2019-02-28
MY169670A (en) 2019-05-08
US20200171027A1 (en) 2020-06-04
FR15C0071I2 (fr) 2016-02-12
JP2012051915A (ja) 2012-03-15
EP1663240A1 (en) 2006-06-07
HK1092698A1 (en) 2007-02-16
CY2016049I2 (el) 2017-07-12
FR15C0073I2 (fr) 2016-02-12
FR15C0071I1 (lt) 2015-04-12

Similar Documents

Publication Publication Date Title
LU92853I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
LU92496I2 (fr) Combinaison de dapagliflozine ou d'un sel pharmaceutiquement acceptable de celle-ci et de merformineou d'un sel pharmaceutiquement acceptable de cell-ci, telle que protégée par le brevet de base EP1506211 B1
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
ATE454138T1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EE05107B1 (et) Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine
MA27372A1 (fr) Forme posologique de pramipexole à administration une fois par jour
BR0209020A (pt) Composição farmacêutica de polialilamina
WO2003103603A3 (en) Novel formate salt of o-desmethyl-venlafaxine
EP1450803A4 (en) NEW USES FOR ANTIMALARIAL THERAPEUTIC AGENTS
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
EP1800693A4 (en) ADJUVANT THERAPY USING ANTI-GLYPICAN-3 ANTIBODY
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
ATE308522T1 (de) Opioidrezeptorantagonisten
SE0102440D0 (sv) New compound
DK1267847T3 (da) 5HT2-antagonist til regulering af IOP og behandling af glaucom
ATE469642T1 (de) Vorbeugungs- oder heilmittel gegen endometriose
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
IL165851A0 (en) The use of benziselenazolone compounds in the preparation of medicament against ischemic myocardial injury
DE60230785D1 (de) Polymorphe marker die benutzt werden kann, um die wirksamkeit der interferon-therapie festzustellen
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine